Evidence map›Paper›PMID 38861282›Full record

ArticleFuture oncology (London, England)2024

Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.

Rafael Fonseca, Adriana Rossi, Rohan Medhekar, Jennifer Voelker, Trevor Homan, Jessica Wilcock, Anna Karakusevic, James Cochrane, Daisy Bridge, Richard Perry and 2 more

Abstract readConsensus Statement
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rafael FonsecaDivision of Hematology and Medical Oncology, Mayo Clinic in Arizona, Phoenix, AZ, USA.ORCID 0000-0002-5938-3769
Adriana RossiIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Rohan MedhekarJanssen Scientific Affairs, Horsham, PA, USA.
Jennifer VoelkerJanssen Scientific Affairs, Horsham, PA, USA.
Trevor HomanJanssen Medical Affairs, Horsham, PA, USA.
Jessica WilcockAdelphi Values PROVE, Bollington, UK.
Anna KarakusevicAdelphi Values PROVE, Bollington, UK.
James CochraneAdelphi Values PROVE, Bollington, UK.
Daisy BridgeAdelphi Values PROVE, Bollington, UK.
Richard PerryAdelphi Values PROVE, Bollington, UK.
Shuchita KailaJanssen Scientific Affairs, Horsham, PA, USA.
Faith E DaviesPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Yi Lin · 2015 to 2026
$25.5M
Janssen Scientific Affairs, LLCNCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Delphi TechniqueMultiple MyelomaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodHumansTreatment OutcomeAntibodies, MonoclonaldaratumumabDelphi panelfirst-line treatmentnewly diagnosed multiple myelomaprescribing patternstransplant-ineligible

Identifiers

PMID38861282
PMCPMC11485956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.